Raymond James Financial Services Advisors, Inc. Zymeworks Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	BUY	$4.65 - $7.43 $10,606 - $16,947	2,281 Added 3.25%	72,524 $446,000
Q2 2022 Aug 12, 2022	SELL	$4.82 - $7.7 $8,309 - $13,274	-1,724 Reduced 2.4%	70,243 $372,000
Q1 2022 May 11, 2022	BUY	$6.0 - $16.98 $47,208 - $133,598	7,868 Added 12.27%	71,967 $471,000
Q4 2021 Feb 08, 2022	SELL	$15.19 - $29.33 $174,168 - $336,297	-11,466 Reduced 15.17%	64,099 $1.05 Million
Q3 2021 Nov 02, 2021	SELL	$27.35 - $37.28 $12,526 - $17,074	-458 Reduced 0.6%	75,565 $2.19 Million
Q2 2021 Aug 11, 2021	BUY	$26.5 - $38.23 $31,084 - $44,843	1,173 Added 1.57%	76,023 $2.64 Million
Q1 2021 May 14, 2021	BUY	$29.83 - $56.81 $310,918 - $592,130	10,423 Added 16.18%	74,850 $2.36 Million
Q4 2020 Feb 12, 2021	SELL	$39.12 - $54.99 $37,750 - $53,065	-965 Reduced 1.48%	64,427 $3.05 Million
Q3 2020 Nov 04, 2020	BUY	$29.21 - $46.58 $630,760 - $1.01 Million	21,594 Added 49.3%	65,392 $3.05 Million
Q2 2020 Jul 17, 2020	BUY	$33.67 - $40.0 $47,845 - $56,840	1,421 Added 3.35%	43,798 $1.58 Million
Q1 2020 Apr 21, 2020	SELL	$24.28 - $49.8 $201,693 - $413,688	-8,307 Reduced 16.39%	42,377 $1.5 Million
Q4 2019 Feb 12, 2020	BUY	$24.84 - $45.46 $539,773 - $987,845	21,730 Added 75.05%	50,684 $2.3 Million
Q3 2019 Nov 07, 2019	BUY	$22.78 - $29.08 $659,572 - $841,982	28,954 New	28,954 $718,000

Others Institutions Holding ZYME

# of Institutions

Shares Held

296K

Call Options Held

Put Options Held

Strategic Wealth Advisors Group, LLC Sacramento, CA

296K
Shares

$4.35 Million
0.08% of portfolio

View Full List

About Zymeworks Inc.

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $905M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

More about ZYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account